174968-68-4Relevant academic research and scientific papers
Synthesis and biological evaluation of 1‐(Diarylmethyl)‐1h‐1,2,4‐triazoles and 1‐(diarylmethyl)‐1h‐imidazoles as a novel class of anti‐mitotic agent for activity in breast cancer
Ana, Gloria,Kelly, Patrick M.,Malebari, Azizah M.,Noorani, Sara,Nathwani, Seema M.,Twamley, Brendan,Fayne, Darren,O’boyle, Niamh M.,Zisterer, Daniela M.,Pimentel, Elisangela Flavia,Endringer, Denise Coutinho,Meegan, Mary J.
, p. 1 - 59 (2021/03/16)
We report the synthesis and biochemical evaluation of compounds that are designed as hybrids of the microtubule targeting benzophenone phenstatin and the aromatase inhibitor letrozole. A preliminary screening in estrogen receptor (ER)‐positive MCF‐7 breast cancer cells identified 5‐((2H‐1,2,3‐triazol‐1‐yl)(3,4,5‐trimethoxyphenyl)methyl)‐2‐methoxyphenol 24 as a potent antiproliferative compound with an IC50 value of 52 nM in MCF‐7 breast cancer cells (ER+/PR+) and 74 nM in triple‐negative MDA‐MB‐231 breast cancer cells. The compounds demonstrated significant G2/M phase cell cycle arrest and induction of apoptosis in the MCF‐7 cell line, inhibited tubulin polymerisation, and were selective for cancer cells when evaluated in non-tumorigenic MCF‐10A breast cells. The immunofluorescence staining of MCF‐7 cells confirmed that the compounds targeted tubulin and induced multinucleation, which is a recognised sign of mitotic catastrophe. Computational docking studies of compounds 19e, 21l, and 24 in the colchicine binding site of tubulin indicated potential binding conformations for the compounds. Compounds 19e and 21l were also shown to selectively inhibit aromatase. These compounds are promising candidates for development as antiproliferative, aromatase inhibitory, and microtubule‐disrupting agents for breast cancer.
Synthesis, anticancer evaluation, and molecular docking studies of benzoxazole linked combretastatin analogues
Babu, Ala Vasu,Kumar, Vukoti Kiran,Prasad, K. R. S.,Puli, Venkat Swamy,Ruddarraju, Radhakrishnam Raju
, (2020/01/28)
A novel series of benzoxazole linked combretastatin derivatives (11a–11n) have been synthesized and confirmed by 1H NMR, 13C NMR, and Mass spectral analysis. The synthesized compounds (11a–11n) were screened for anticancer activity against three human cancer cell lines, Breast (MCF-7), Lung (A549), and Melanoma (A375). Most of the compounds exhibit moderate to potent anticancer activity. Among the compounds, 11g, 11h, 11l, 11m, and 11n showed more potent activity than the positive control Doxorubicin. In addition, compounds 11g, 11l, 11m, and 11n were carried out their molecular docking studies on EGFR receptor (PDB ID: 4hjo) and results indicated that 11g and 11l have strong binding interactions with the receptor. It was found that the binding energy calculations were in good agreement with the observed IC50 values.
Antineoplastic agents. 443. Synthesis of the cancer cell growth inhibitor hydroxyphenstatin and its sodium diphosphate prodrug
Pettit, George R.,Grealish, Matthew P.,Herald, Delbert L.,Boyd, Michael R.,Hamel, Ernest,Pettit, Robin K.
, p. 2731 - 2737 (2007/10/03)
A structure - activity relationship (SAR) study of the South African willow tree (Combretum caffrum) antineoplastic constituent combretastatin A-4 (3b) led to the discovery of a potent cancer cell growth inhibitor designated phenstatin (5a). This benzophenone derivative of combretastatin A-4 showed remarkable antineoplastic activity, and the benzophenone derivative of combretastatin A-1 was therefore synthesized. The benzophenone, designated hydroxyphenstatin (6a), was synthesized by coupling of a protected bromobenzene and a benzaldehyde to give the benzhydrol with subsequent oxidation to the ketone. Hydroxyphenstatin was converted to the sodium phosphate prodrug (6e) by a dibenzyl phosphite phosphorylation and subsequent benzyl cleavage (6a → 6d → 6e). While hydroxyphenstatin (6a) was a potent inhibitor of tubulin polymerization with activity comparable to that of combretastatin A-1 (3a), the phosphorylated derivative (6e) was inactive.
On the silylation of diarylcarbinols
Gautret, Philippe,El-Ghammarti, Samira,Legrand, Anne,Couturier, Daniel,Rigo, Benoit
, p. 707 - 713 (2007/10/03)
Because of their dismutation into benzophenones and diphenylmethanes, it is necessary to use chlorotrimethylsilane and not triflic acid as a catalyst for the silylation of diarylcarbinol with hexamethyl-disilazane.
